Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England
Zaccardi F, Ling S, Gillies CL, et al.
Lancet Diabetes Endocrinol. Pub. online 19 Nov 2025.
Leggi
Breaking news
Metabolic improvement mediates the causal relationship between GLP-1 receptor agonists and myocardial infarction: a mendelian randomization and mediation analysis study
Tong J, Li N, Hu F, Yue Y
Diabetes Care. Pub. online 19 Nov 2025.
Leggi
Challenges and opportunities for improving care for type 1 diabetes in older adulthood
Kahkoska AR, Neumiller JJ, Alexopoulos AS, et al.
Diabetes Care. Pub. online 20 Nov 2025.
Leggi
Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: an umbrella review and evidence map of randomised controlled trials
Yeo D, Jo Y, Jeong J, et al.
Diabetes Obes Metab. Pub. online 19 Nov 2025.
Leggi
Built environment and the evolution of cardiometabolic risk factors: a systematic review and meta-analysis of longitudinal studies
Feyissa TR, Beks H, Tolossa T, et al.
BMC Med. Pub. online 17 Nov 2025.
Leggi
Peripheral neuropathy: a review
Mauermann ML, Staff NP
JAMA. Pub. online 17 Nov 2025.
Leggi
Artificial intelligence-driven clinical decision support systems to assist healthcare professionals and people with diabetes in Europe at the point of care: a Delphi-based consensus roadmap
Bajramagic M, Battelino T, Cos X, et al.
Diabetologia. Pub. online 17 Nov 2025.
Leggi
Inflammatory and insulinemic dietary patterns and risk of type 2 diabetes among women with a history of gestational diabetes mellitus: a prospective study of 84,174 person-years of follow-up
Liu P, Yang J, Lee DH, et al.
Diabetes Care. Pub. online 14 Nov 2025.
Leggi
EMA: First-in-class treatment to delay onset of type 1 diabetes. Teizeild significantly delays onset of stage 3 diabetes and preserves functioning of cells producing insulin
14/11/2025
Leggi
Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial
Ziegler AG, Achenbach P, Weiß A, et al.
Lancet. Pub. online 11 Nov 2025.
Leggi